dermal lymphatic endothelial cells Search Results


94
Cell Applications Inc primary human dermal lymphatic microvascular endothelial cells hdlmvecs
Primary Human Dermal Lymphatic Microvascular Endothelial Cells Hdlmvecs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dermal+lymphatic+endothelial+cells/pmc07019401-147-7-18?v=Cell+Applications+Inc
Average 94 stars, based on 1 article reviews
primary human dermal lymphatic microvascular endothelial cells hdlmvecs - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

N/A
Primary Human Dermal Lymphatic Endothelial Cells isolated from different sources (e.g. juvenile foreskin). CD31 positive, Podoplanin positive. Primary Human Dermal Lymphatic Endothelial Cells (HDLEC) are a subpopulation of the Human Dermal Endothelial Cells. They are
  Buy from Supplier

90
ScienCell human dermal lymphatic endothelial cells (hdlecs)
(A): HMGB1 promoted VEGF-C-induced <t>HDLECs</t> proliferation in a dose-dependent manner. (B): TLR4 mediates HMGB1-induced LECs proliferation. (C-E): TLR4 mediates HMGB1-induced LECs tube formation.* p < 0.05, ** p < 0.01, *** p < 0.001
Human Dermal Lymphatic Endothelial Cells (Hdlecs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dermal+lymphatic+endothelial+cells/pmc04839690-61-0-9?v=ScienCell
Average 90 stars, based on 1 article reviews
human dermal lymphatic endothelial cells (hdlecs) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
BioMimetic Therapeutics human dermal microvascular lymphatic endothelial cells (lecs)
(A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic <t>endothelial</t> identity and cell morphology in the channel. (B) Morphologic changes in human dermal <t>microvascular</t> blood endothelial cells (BECs) with lymphatic endothelial cells <t>(LECs)</t> after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.
Human Dermal Microvascular Lymphatic Endothelial Cells (Lecs), supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dermal+lymphatic+endothelial+cells/pmc09274261-174-6-16?v=BioMimetic+Therapeutics
Average 90 stars, based on 1 article reviews
human dermal microvascular lymphatic endothelial cells (lecs) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
AngioBio Inc human neonatal dermal lymphatic endothelial cells (lec
Suppression of vascular endothelial growth factor <t>(VEGF)‐C‐driven</t> <t>lymphatic</t> endothelial cell <t>(LEC)</t> proliferation by conditioned medium of soluble vascular endothelial growth factor receptor‐3 (sVEGFR‐3)‐expressing cells. Cells were plated at 5 × 103 cells/well in 96‐well plates, and 50% sVEGFR‐3‐conditioned medium or luciferase‐conditioned medium was added with 100 ng/mL recombinant human VEGF‐C. The number of LEC with 50% sVEGFR‐3‐conditioned medium (b) was clearly smaller than that with control (a). The cells were counted by colorimetric assay 48 h after plating. Each bar represents the mean ± SD. (*P < 0.01) (c).
Human Neonatal Dermal Lymphatic Endothelial Cells (Lec, supplied by AngioBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dermal+lymphatic+endothelial+cells/pmc07657111-66-0-10?v=AngioBio+Inc
Average 90 stars, based on 1 article reviews
human neonatal dermal lymphatic endothelial cells (lec - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc human dermal lymphatic microvascular endothelial cells (lec)
Suppression of vascular endothelial growth factor <t>(VEGF)‐C‐driven</t> <t>lymphatic</t> endothelial cell <t>(LEC)</t> proliferation by conditioned medium of soluble vascular endothelial growth factor receptor‐3 (sVEGFR‐3)‐expressing cells. Cells were plated at 5 × 103 cells/well in 96‐well plates, and 50% sVEGFR‐3‐conditioned medium or luciferase‐conditioned medium was added with 100 ng/mL recombinant human VEGF‐C. The number of LEC with 50% sVEGFR‐3‐conditioned medium (b) was clearly smaller than that with control (a). The cells were counted by colorimetric assay 48 h after plating. Each bar represents the mean ± SD. (*P < 0.01) (c).
Human Dermal Lymphatic Microvascular Endothelial Cells (Lec), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dermal+lymphatic+endothelial+cells/pmc03073416-50-16-32?v=STEMCELL+Technologies+Inc
Average 90 stars, based on 1 article reviews
human dermal lymphatic microvascular endothelial cells (lec) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Avantor human dermal lymphatic endothelial cells (hdlecs
Suppression of vascular endothelial growth factor <t>(VEGF)‐C‐driven</t> <t>lymphatic</t> endothelial cell <t>(LEC)</t> proliferation by conditioned medium of soluble vascular endothelial growth factor receptor‐3 (sVEGFR‐3)‐expressing cells. Cells were plated at 5 × 103 cells/well in 96‐well plates, and 50% sVEGFR‐3‐conditioned medium or luciferase‐conditioned medium was added with 100 ng/mL recombinant human VEGF‐C. The number of LEC with 50% sVEGFR‐3‐conditioned medium (b) was clearly smaller than that with control (a). The cells were counted by colorimetric assay 48 h after plating. Each bar represents the mean ± SD. (*P < 0.01) (c).
Human Dermal Lymphatic Endothelial Cells (Hdlecs, supplied by Avantor, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dermal+lymphatic+endothelial+cells/pmc10706153-81-0-6?v=Avantor
Average 90 stars, based on 1 article reviews
human dermal lymphatic endothelial cells (hdlecs - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier


N/A
Human Dermal Lymphatic Endothelial Cells
  Buy from Supplier

N/A
BKS db Mouse Dermal Lymphatic Endothelial Cells are isolated from the dermal lymphatic of Mice homozygous for the diabetes spontaneous mutation (Lepr/db) manifest morbid obesity, chronic hyperglycemia, pancreatic beta cell atrophy and become hypoRIemic. BKS
  Buy from Supplier

N/A
Primary Human Dermal Lymphatic Endothelial Cells isolated from different sources (e.g. juvenile foreskin). CD31 positive, Podoplanin positive. Primary Human Dermal Lymphatic Endothelial Cells (HDLEC) are a subpopulation of the Human Dermal Endothelial Cells. They are
  Buy from Supplier


Image Search Results


(A): HMGB1 promoted VEGF-C-induced HDLECs proliferation in a dose-dependent manner. (B): TLR4 mediates HMGB1-induced LECs proliferation. (C-E): TLR4 mediates HMGB1-induced LECs tube formation.* p < 0.05, ** p < 0.01, *** p < 0.001

Journal: PLoS ONE

Article Title: High Mobility Group Box-1 Promotes Inflammation-Induced Lymphangiogenesis via Toll-Like Receptor 4-Dependent Signalling Pathway

doi: 10.1371/journal.pone.0154187

Figure Lengend Snippet: (A): HMGB1 promoted VEGF-C-induced HDLECs proliferation in a dose-dependent manner. (B): TLR4 mediates HMGB1-induced LECs proliferation. (C-E): TLR4 mediates HMGB1-induced LECs tube formation.* p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Human dermal lymphatic endothelial cells (HDLECs) were purchased from ScienCell (Carlsbad, CA) and maintained in endothelial cell basal medium-2 with growth supplements (EBM-2 MV).

Techniques:

(A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic endothelial identity and cell morphology in the channel. (B) Morphologic changes in human dermal microvascular blood endothelial cells (BECs) with lymphatic endothelial cells (LECs) after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.

Journal: Microcirculation (New York, N.Y. : 1994)

Article Title: A bioengineered lymphatic vessel model for studying lymphatic endothelial cell-cell junction and barrier function

doi: 10.1111/micc.12730

Figure Lengend Snippet: (A) A schematic of an organotypic 3D lymphatic vessel model (LV-on-chip). Prox-1 (green) and CD31 (red) expression confirms lymphatic endothelial identity and cell morphology in the channel. (B) Morphologic changes in human dermal microvascular blood endothelial cells (BECs) with lymphatic endothelial cells (LECs) after one day of cell seeding. BECs become more contractile than LECs, forming a smaller vessel diameter compared to LECs. (C) BVs and LVs observed in mouse ear tissues. mLYVE-1, anti-mouse LYVE-1 antibody; mCD31, anti-mouse CD31 antibody. (D) Phalloidin (red) and anti-VE-cad (VE-cadherin) antibody (green) staining to visualize F-actin and adherens junctions. (E) Lymphatic and blood vessel barrier function. 70 kDa dextran was introduced into the vessel lumens and dextran diffusion was observed in real time under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (F) Quantification of the permeability of BEC-generated engineered BVs and LEC-generated LVs. ** p = 0.0016, two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M.

Article Snippet: In the hollow channel, we seeded human dermal microvascular lymphatic endothelial cells (LECs) to form a biomimetic lymphatic vessel ( ).

Techniques: Expressing, Staining, Diffusion-based Assay, Microscopy, Permeability, Generated, Two Tailed Test

(A) Lymphatic endothelial cells (LECs) in different ECM hydrogels (2D): 2.5 mg/ml collagen 1, 2.5 mg/ml collagen 1 and 150 μg/ml Fibronectin, and no gel (plastic). F-actin and VE-cad were visualized to assess cytoskeletal arrangement and adherens junction formation in each condition. (B) Quantification of the relative junction area was performed, illustrating a significantly lower junction area in cells grown on the 2.5 mg/ml collagen 1 compared to the cells grown directly on plastic. ** p = 0.0017 (Collagen 1 vs. plastic); higher junction area in cells grown on the 2.5 mg/ml collagen 1 + fibronectin compared to the cells grown on collagen 1. * p = 0.0151 (Collagen 1 + fibronectin vs. Collagen 1); not-significant (ns) p = 0.5292 (Collagen 1 + fibronectin vs plastic). One-way ANOVA with Tukey’s HSD tests , n = 6 per group. Data are expressed as mean ± S.E.M. (C) Dynamics of fibronectin on LECs in collagen 1 or collagen 1 + fibronectin gel. On collagen 1 gel, LEC islands with VE-cad expression lacks fibronectin expression. On collagen 1 + fibronectin, fibronectin connects separate LEC islands. (D) At day 4 on Collagen 1 + fibronectin, LECs showed tightened junctions and fibronectin was localized in the junctional area.

Journal: Microcirculation (New York, N.Y. : 1994)

Article Title: A bioengineered lymphatic vessel model for studying lymphatic endothelial cell-cell junction and barrier function

doi: 10.1111/micc.12730

Figure Lengend Snippet: (A) Lymphatic endothelial cells (LECs) in different ECM hydrogels (2D): 2.5 mg/ml collagen 1, 2.5 mg/ml collagen 1 and 150 μg/ml Fibronectin, and no gel (plastic). F-actin and VE-cad were visualized to assess cytoskeletal arrangement and adherens junction formation in each condition. (B) Quantification of the relative junction area was performed, illustrating a significantly lower junction area in cells grown on the 2.5 mg/ml collagen 1 compared to the cells grown directly on plastic. ** p = 0.0017 (Collagen 1 vs. plastic); higher junction area in cells grown on the 2.5 mg/ml collagen 1 + fibronectin compared to the cells grown on collagen 1. * p = 0.0151 (Collagen 1 + fibronectin vs. Collagen 1); not-significant (ns) p = 0.5292 (Collagen 1 + fibronectin vs plastic). One-way ANOVA with Tukey’s HSD tests , n = 6 per group. Data are expressed as mean ± S.E.M. (C) Dynamics of fibronectin on LECs in collagen 1 or collagen 1 + fibronectin gel. On collagen 1 gel, LEC islands with VE-cad expression lacks fibronectin expression. On collagen 1 + fibronectin, fibronectin connects separate LEC islands. (D) At day 4 on Collagen 1 + fibronectin, LECs showed tightened junctions and fibronectin was localized in the junctional area.

Article Snippet: In the hollow channel, we seeded human dermal microvascular lymphatic endothelial cells (LECs) to form a biomimetic lymphatic vessel ( ).

Techniques: Expressing

(A) Activated integrin α5 was visualized in both ECM composition conditions by using anti-integrin α5 antibody (clone: SNAKA51) that can only detect the activated form of the integrin α5. F-actin was also observed in these conditions. (B) LECs in Collagen 1 were pre-treated with anti-integrin α5 antibodies (clone: SNAKA51) antibodies to activate integrin α5 in LECs. The fixed samples were stained with anti-VE-cadherin antibodies, anti-JAM-A antibodies, and phalloidin to visualize adherens junctions and F-actin. (C) Quantification of the relative junction area was performed, illustrating a significantly higher junction area in integrin α5 activated cells compared to the control LECs. ** p = 0.0020; Two tailed unpaired Student t-test, n = 6 per group. Data are expressed as mean ± S.E.M. (D) Control LECs or LECs with activated integrin α5 were seeded in LV-on-chip and cultured for 3 days on the rocking platform. 70 kDa dextran was introduced to the lymphatic lumens. Dextran diffusion was observed at 0 and 1 minutes under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (E) Quantification of the permeability of LEC-generated engineered LVs in collagen 1 with and without integrin α5 activation. ** p = 0.0021. Two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M. (F) This table summarizes our findings regarding LEC permeability and integrin α5 activity. LVs grown in Collagen 1 without any activator treatment showed high LEC permeability and low integrin α5 activity. In contrast, LVs grown in either Collagen 1 + Fibronectin or LVs grown in only Collagen 1 with integrin α5 activator pre-treatment both showed low LEC permeability and high integrin α5 activity.

Journal: Microcirculation (New York, N.Y. : 1994)

Article Title: A bioengineered lymphatic vessel model for studying lymphatic endothelial cell-cell junction and barrier function

doi: 10.1111/micc.12730

Figure Lengend Snippet: (A) Activated integrin α5 was visualized in both ECM composition conditions by using anti-integrin α5 antibody (clone: SNAKA51) that can only detect the activated form of the integrin α5. F-actin was also observed in these conditions. (B) LECs in Collagen 1 were pre-treated with anti-integrin α5 antibodies (clone: SNAKA51) antibodies to activate integrin α5 in LECs. The fixed samples were stained with anti-VE-cadherin antibodies, anti-JAM-A antibodies, and phalloidin to visualize adherens junctions and F-actin. (C) Quantification of the relative junction area was performed, illustrating a significantly higher junction area in integrin α5 activated cells compared to the control LECs. ** p = 0.0020; Two tailed unpaired Student t-test, n = 6 per group. Data are expressed as mean ± S.E.M. (D) Control LECs or LECs with activated integrin α5 were seeded in LV-on-chip and cultured for 3 days on the rocking platform. 70 kDa dextran was introduced to the lymphatic lumens. Dextran diffusion was observed at 0 and 1 minutes under microscopy. Superimposed red dashed lines represent the edges of the vessel lumens. (E) Quantification of the permeability of LEC-generated engineered LVs in collagen 1 with and without integrin α5 activation. ** p = 0.0021. Two tailed unpaired Student t-test, n = 5 per group. Data are expressed as mean ± S.E.M. (F) This table summarizes our findings regarding LEC permeability and integrin α5 activity. LVs grown in Collagen 1 without any activator treatment showed high LEC permeability and low integrin α5 activity. In contrast, LVs grown in either Collagen 1 + Fibronectin or LVs grown in only Collagen 1 with integrin α5 activator pre-treatment both showed low LEC permeability and high integrin α5 activity.

Article Snippet: In the hollow channel, we seeded human dermal microvascular lymphatic endothelial cells (LECs) to form a biomimetic lymphatic vessel ( ).

Techniques: Staining, Control, Two Tailed Test, Cell Culture, Diffusion-based Assay, Microscopy, Permeability, Generated, Activation Assay, Activity Assay

Suppression of vascular endothelial growth factor (VEGF)‐C‐driven lymphatic endothelial cell (LEC) proliferation by conditioned medium of soluble vascular endothelial growth factor receptor‐3 (sVEGFR‐3)‐expressing cells. Cells were plated at 5 × 103 cells/well in 96‐well plates, and 50% sVEGFR‐3‐conditioned medium or luciferase‐conditioned medium was added with 100 ng/mL recombinant human VEGF‐C. The number of LEC with 50% sVEGFR‐3‐conditioned medium (b) was clearly smaller than that with control (a). The cells were counted by colorimetric assay 48 h after plating. Each bar represents the mean ± SD. (*P < 0.01) (c).

Journal: Cancer Science

Article Title: Suppression of lymph node and lung metastases of endometrial cancer by muscle‐mediated expression of soluble vascular endothelial growth factor receptor‐3

doi: 10.1111/cas.12184

Figure Lengend Snippet: Suppression of vascular endothelial growth factor (VEGF)‐C‐driven lymphatic endothelial cell (LEC) proliferation by conditioned medium of soluble vascular endothelial growth factor receptor‐3 (sVEGFR‐3)‐expressing cells. Cells were plated at 5 × 103 cells/well in 96‐well plates, and 50% sVEGFR‐3‐conditioned medium or luciferase‐conditioned medium was added with 100 ng/mL recombinant human VEGF‐C. The number of LEC with 50% sVEGFR‐3‐conditioned medium (b) was clearly smaller than that with control (a). The cells were counted by colorimetric assay 48 h after plating. Each bar represents the mean ± SD. (*P < 0.01) (c).

Article Snippet: Human neonatal dermal lymphatic endothelial cells (LEC) were purchased from AngioBio (Del Mar, CA, USA) and maintained in EGM‐MV2 BulletKit (Cambrex, East Rutherford, NJ, USA) supplemented with 10% inactivated FCS at 37°C in a 5% CO 2 atmosphere.

Techniques: Expressing, Luciferase, Recombinant, Colorimetric Assay